Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

CDC Awards ICF $20 Million Health Informatics and Surveillance Task Order


FAIRFAX, Va., Aug. 16, 2018 /PRNewswire/ -- ICF (NASDAQ: ICFI), a global consulting and digital services provider, was recently awarded a re-compete task order by the U.S. Centers for Disease Control and Prevention (CDC), Center for Surveillance, Epidemiology, and Laboratory Services (CSELS) to support multiple aspects of its BioSense program, CDC's cloud-based public health surveillance system.

(PRNewsfoto/ICF International)

The task order, which was awarded by the Division of Health Informatics and Surveillance (DHIS), has a value of $20 million and a term of one base year and two options years.

Part of the national emergency preparedness system, the BioSense syndromic surveillance system increases the ability of local, state and national health officials to monitor and respond to the harmful health effects of exposure to disease, addiction and hazardous conditions.

"Over the past few years, ICF has helped CDC significantly increase the national coverage of data providers and the number of jurisdictions and users that are supported by BioSense," said Terence McKittrick, senior vice president for ICF. "The BioSense system stores nearly 40 terabytes of data, information crucial to the surveillance of important health issues such as the nation's opioid crisis. We look forward to working with CDC to continue to improve this critical public health information system."

ICF will provide expertise and support services to BioSense in the areas of surveillance, information management, technology and data management and analytics. Specifically, the company will help CDC expand of the scale and scope of the platform by continuing to help improve the quality of its surveillance data, enhance the technology of the BioSense platform and expand its coverage to build nationwide situational awareness capabilities with federal, state and local partners.

Read more about ICF's public health services including health informatics, data management and disease surveillance.

About ICF
ICF is a global consulting services company with over 5,500 specialized experts, but we are not your typical consultants. At ICF, business analysts and policy specialists work together with digital strategists, data scientists and creatives. We combine unmatched industry expertise with cutting-edge engagement capabilities to help organizations solve their most complex challenges. Since 1969, public and private sector clients have worked with ICF to navigate change and shape the future. Learn more at icf.com.

Caution Concerning Forward-looking Statements
Statements that are not historical facts and involve known and unknown risks and uncertainties are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such statements may concern our current expectations about our future results, plans, operations and prospects and involve certain risks, including those related to the government contracting industry generally; our particular business, including our dependence on contracts with U.S. federal government agencies; and our ability to acquire and successfully integrate businesses. These and other factors that could cause our actual results to differ from those indicated in forward-looking statements are included in the "Risk Factors" section of our securities filings with the Securities and Exchange Commission. The forward-looking statements included herein are only made as of the date hereof, and we specifically disclaim any obligation to update these statements in the future.

Contact:  Lauren Dyke, [email protected], +1.571.373.5577

SOURCE ICF


These press releases may also interest you

at 17:44
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...

at 17:30
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association...

at 17:19
Long-time Madison podiatrist Colin Graney, DPM, has announced both the closing of his practice and that the Board Certified and Fellowship Trained physicians at Orthopedic & Spine Centers of Wisconsin will provide continuing care for his patients....

at 17:03
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary...

at 16:42
Accelerate Diagnostics, Inc. today announced financial preliminary results for the first quarter ended March 31, 2024. "During the...



News published on and distributed by: